Citations

Clear

1011 citation(s) found for "Barry, WT".

Fontan haemodynamics in adults with obesity compared with overweight and normal body mass index: a retrospective invasive exercise study
Opp, Derek N., Jain, C. Charles , Egbe, A, Borlaug, Barry A. , Reddy, Yogesh N.V. , Connolly, Heidi M, Lara-Breitinger, Kyla , Miranda, William R. , Reddy, Yogesh V, Lara-Breitinger, Kyla M , Miranda, William R , Nishimura, Rick , Borlaug, Barry A , Egbe, Alexander C. , Connolly, Heidi M. , Cordina, Rachael

Mayo Clinic

European Journal of Preventive Cardiology | September 28, 2024 | Volume: 32 | Issue: 3 | Pages: 221-230

10.1093/eurjpc/zwae314 | PMID 39340418 Get It

Abstract Aims The effects of obesity on Fontan haemodynamics are poorly understood. Accordingly, we assessed its impact on exercise invasive haemodynamics and exercise capacity. Methods and results Seventy-seven adults post-Fontan undergoing exercise cardiac catheterization (supine cycle protocol) were retrospectively identified using an institutional database and categorized according to the presence of obesity [body mass index (BMI) > 30 kg/m2] and overweight/normal BMI (BMI ≤ 30 kg/m2). There were 18 individuals with obesity (BMI 36.4 ± 3 kg/m2) and 59 with overweight/normal BMI (BMI 24.1 ± 3.6 kg/m2). Peak oxygen consumption (VO2) on non-invasive cardiopulmonary exercise testing was lower in patients with obesity (15.6 ± 3.5 vs. 19.6 ± 5.8 mL/kg/min, P = 0.04). At rest, systemic flow (Qs) [7.0 (4.8; 8.3) vs. 4.8 (3.9; 5.8) L/min, P = 0.001], pulmonary artery (PA) pressure (16.3 ± 3.5 vs. 13.1 ± 3.5 mmHg, P = 0.002), and PA wedge pressure (PAWP) (11.7 ± 4.4 vs. 8.9 ± 3.1 mmHg, P = 0.01) were higher, while arterial O2 saturation was lower [89.5% (86.5; 92.3) vs. 93% (90; 95)] in obesity compared with overweight/normal BMI. Similarly, patients with obesity had higher exercise PA pressure (29.7 ± 6.5 vs. 24.7 ± 6.8 mmHg, P = 0.01) and PAWP (23.0 ± 6.5 vs. 19.8 ± 7.3 mmHg, P = 0.047), but lower arterial O2 saturation [82.4 ± 7.0% vs. 89% (85; 92), P = 0.003]. Conclusion Adults post-Fontan with obesity have worse aerobic capacity, increased Qs, higher filling pressures, and decreased arterial O2 saturation compared with those with overweight/normal BMI, both at rest and during exercise, mirroring the findings observed in the obesity phenotype of heart failure with preserved ejection fraction. Whether treating obesity and its cardiometabolic sequelae in Fontan patients will improve haemodynamics and outcomes requires further study.
Sexual Dimorphism in the Relationships Between Intramyocardial Fat, Myocardial Fibrosis, and Exercise Intolerance in Heart Failure with Preserved Ejection Fraction
Dong, Xin , Koepp, Katlyn E. , Sorimachi, Hidemi, Araoz, Philip A. , Delgado, Victoria , Bax, Jeroen J., Araoz, Philip, Delgado, Victoria , Ng, Arnold C.T. , Obokata, Masaru , Galloway, Graham J. , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | September 24, 2024 | Volume: 27 | Issue: 7 | Pages: 1359-1361

10.1002/ejhf.3473 | PMID 39315640 Get It

The Role of Cardiovascular Imaging in the Diagnosis of Athlete’s Heart: Navigating the Shades of Grey
Ali, Nima Baba , Esfahani, Sogol Attaripour , Scalia, Isabel G. , Farina, Juan M. , Pereyra, Milagros , Barry, Timothy , Lester, Steven J., Alsidawi, Said , Steidley, D. Eric , Ayoub, Chadi , Palermi, Stefano , Arsanjani, Reza , Baba Ali, Nima , Attaripour Esfahani, Sogol, Steidley, David E, Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Alsidawi, Said , Scalia, Isabel G

Mayo Clinic

Journal of Imaging | September 16, 2024 | Volume: 10 | Issue: 9 | Pages: 230

10.3390/jimaging10090230 | PMID 39330450 Get It

Athlete’s heart (AH) represents the heart’s remarkable ability to adapt structurally and functionally to prolonged and intensive athletic training. Characterized by increased left ventricular (LV) wall thickness, enlarged cardiac chambers, and augmented cardiac mass, AH typically maintains or enhances systolic and diastolic functions. Despite the positive health implications, these adaptations can obscure the difference between benign physiological changes and early manifestations of cardiac pathologies such as dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and arrhythmogenic cardiomyopathy (ACM). This article reviews the imaging characteristics of AH across various modalities, emphasizing echocardiography, cardiac magnetic resonance (CMR), and cardiac computed tomography as primary tools for evaluating cardiac function and distinguishing physiological adaptations from pathological conditions. The findings highlight the need for precise diagnostic criteria and advanced imaging techniques to ensure accurate differentiation, preventing misdiagnosis and its associated risks, such as sudden cardiac death (SCD). Understanding these adaptations and employing the appropriate imaging methods are crucial for athletes’ effective management and health optimization.
Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial
Hošková, Eva , VELEBOVA, KATERINA, Veleba, Jiří , Beneš, Jan , Kuda, Ondřej , Segeťová, Markéta , Thieme, Lenka , Pelikánová, Terezie , Kahleová, Hana , Melenovský, Vojtěch , Borlaug, Barry A. , Čajka, Tomáš , Kopecký, Ján , Pelikánová, Terezie , Haluzı́k, Martin , Hill, Martin

Mayo Clinic

Clinical Diabetes | September 9, 2024 | Volume: 43 | Issue: 1 | Pages: 23-32

10.2337/cd24-0003 | PMID 39829685 Get It

This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.
Response by Kosiborod et al to Letter Regarding Article, “Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial”
Kosiborod, Mikhail , Petrie, Mark C. , Borlaug, Barry A. , Kosiborod, Mikhail N , Borlaug, Barry A , Petrie, Mark C

Mayo Clinic

Circulation | September 3, 2024 | Volume: 150 | Issue: 10 | Pages: No page available

10.1161/circulationaha.124.069707 | PMID 39226383 Get It

Author’s Reply to Different Aortic Root Diameters on Echocardiography and MRI During Pregnancy in Mosaic Turner Syndrome
Majdalany, David , Lee, Hong Seok , Barry, Timothy , Singh, Katherine , Chapa, Jeff , Pettersson, Gösta , Majdalany, David S , Lee, Hong , Pettersson, Gosta B

Mayo Clinic

Korean Circulation Journal | August 28, 2024 | Volume: 54 | Issue: 11 | Pages: 762

10.4070/kcj.2024.2501 | PMID 39434364 Get It

Echocardiographic Hemodynamics Correlate with Differences in DOAC-specific Bleeding and Stroke Rates in Non-Valvular Atrial Fibrillation
O’Shea, Michael P, Yusuf, Ali, Habib, Eiad , Ravi, Srekar , Chao, Chieh Ju, Newton, Sam , Scott, Robert L. , Barry, Timothy , Arsanjani, Reza, O’Shea, Michael , O’Shea, Michael P., Karikalan, Suganya Arunachalam , Chao, Chieh‐Ju , Ashraf, Hasan , Agasthi, Pradyumna , Arsanjani, Reza , Masry, Hicham El

Mayo Clinic

No container title available | August 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4708572/v1 Get It

Abstract Aims : Direct oral anticoagulants (DOACs) are widely used for stroke prevention in people with non-valvular atrial fibrillation/flutter (NVAF). Anticoagulants have different bleeding profiles. Apixaban is associated with the lowest bleeding risk. This study evaluates the interaction between DOAC used and right ventricular systolic pressure (RVSP) on echocardiogram and bleeding rates. It was hypothesized that pulmonary hypertension may be associated with excess bleeding based on anticoagulant-specific pharmacologic profiles. Methods & Results : A retrospective analysis of a database was conducted. Multivariable regression models for bleeding rates were developed using a causative analysis approach among participants who had undergone an echocardiogram, and interaction terms for DOAC choice were incorporated. Stratum specific estimates were calculated using linear computation. Patients taking Apixaban had lower bleeding rates than those taking Rivaroxaban and Dabigatran. Among those without pulmonary hypertension, there was no difference in bleeding rates. Where RVSP was ≥45mmHg, there was a 90% increase in bleeding rates with use of Dabigatran (HR 1.99, p=0.024) and Rivaroxaban (HR 1.86, p=0.042) compared to Apixaban (Figure 1). Conclusions : Elevated RVSP is associated with excess bleeding in patients taking Rivaroxaban and Dabigatran, but not Apixaban, after controlling for confounding variables.
Lymph node staging and treatment in pediatric patients with soft tissue sarcomas: A consensus opinion from the Children’s Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe
Scheltinga, Scheila E. J. Terwisscha van, Keizer, Bart de , McCarville, M. Beth , Casey, Dana L. , Walterhouse, David , Hiemcke‐Jiwa, Laura S. , Franzius, Christiane, Vokuhl, Christian , Birz, Suzi , Rodeberg, David A. , Casey, Dana L , de Keizer, Bart , Schoot, Reineke A , Routh, Jonathan C. , Seitz, Guido , Kao, Simon C. , Shulkin, Barry L. , Ewijk, Roelof van , Allen‐Rhoades, Wendy , Mercolini, Federico , Merks, Johannes H M , Orbach, Daniel , Kapadia, Tejas , Fajardo, Raquel Dávila , Corti, Federica De , Tang, Vivian , Metts, Jonathan L. , Oberoi, Saphna , Dasgupta, Roshni

Mayo Clinic

No container title available | August 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.172445880.02878798/v1 Get It

Accurate staging of nodal involvement in pediatric sarcoma patients is important to determine correct systemic and local therapy, with the goal to reduce subsequent recurrences. However, differences in lymph node staging strategies, definitions, and treatment protocols between the Children’s Oncology Group (COG), European Pediatric Soft Tissue Sarcoma Study Group (EpSSG), and the Cooperative Weichteil Sarkom Studiengruppe (CWS), complicate comparisons. In this article we try to establish internationally recognized recommendations for lymph node assessment and treatment of children and adolescents diagnosed with RMS and NRSTS according to the Consensus Conference Standard Operating Procedure methodology.
Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma
Paul, Barry , Raza, Shahzad , Mammadzadeh, Aytaj , Khasawneh, B. , Shatnawi, Sara, Ahmed, Nausheen , Mushtaq, Muhammad Umair , Atrash, Shebli , Raza, Shahzad , Khasawneh, Bayan , Ahmed, Nausheen , Atrash, Shebli , Paul, Barry , Anwer, Faiz , McGuirk, Joseph P. , Mahmoudjafari, Zahra , Abdallah, Al-Ola

Mayo Clinic

Cancers | August 23, 2024 | Volume: 16 | Issue: 17 | Pages: 2938

10.3390/cancers16172938 | PMID 39272795 Get It

The use of 4-drug induction regimens for treatment naïve newly diagnosed multiple myeloma (NDMM) is associated with improved depth of response and progression-free survival (PFS). However, head-to-head trials of 4-drug combinations are lacking, and instead, these regimens are typically compared to 3-drug backbones; limiting the ability to discern whether any additional benefit (or toxicity) is simply additive or represents a synergy (or interaction). We conducted a meta-analysis of phase 2 and phase 3 clinical trials that randomized treatment naïve NDMM patients to either a 4-drug or 3-drug induction regimen. We included 11 trials which represented 6509 unique patients. PFS for all trials in the meta-analysis was 54 months with a 4-drug induction and 8.9 months with a 3-drug induction (HR: 0.49; 95% CI: 0.45; 0.54), but there was no benefit to using a 4-drug induction that did not include an anti-CD38 antibody (PFS 4-drug 8.1 months, PFS 3-drug 8.0 months; HR 0.95; 95% CI 0.86; 1.06). Adverse events were more frequent with the quadruplet regimens but were predominately mild. High-grade (≥3) adverse events (AEs) that were more common with 4-drug regimens were infections (RR: 1.34; 95% CI 1.17; 1.54) and thrombocytopenia (RR: 1.39; 95% CI 1.12; 1.74). This study suggests that 4-drug induction regimens which include an anti-CD38 antibody improve efficacy although with additional toxicity in NDMM patients.
Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction
Jain, C. Charles , Melenovský, Vojtěch , Asokan, Aneesh K , Carter, Rickey E. , Jensen, Michael D. , Borlaug, Barry A. , Reddy, Yogesh N.V. , Charles Jain, C , Nair, Sreekumaran, Borlaug, Barry A , Nishimura, Rick , Carter, Rickey E , Melenovský, Vojtěch , Haluzı́k, Martin , Nair, K. Sreekumaran

Mayo Clinic

European Heart Journal | August 22, 2024 | Volume: 45 | Issue: 37 | Pages: 3889-3891

10.1093/eurheartj/ehae534 | PMID 39167062 Get It